Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
Jagsonpal Pharmaceuticals is currently trading at Rs. 341.00, up by 7.70 points or 2.31% from its previous closing of Rs. 333.30 on the BSE.
The scrip opened at Rs. 337.00 and has touched a high and low of Rs. 347.45 and Rs. 337.00 respectively. So far 2073 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 5 has touched a 52 week high of Rs. 513.90 on 31-Jul-2023 and a 52 week low of Rs. 270.05 on 14-Mar-2024.
Last one week high and low of the scrip stood at Rs. 368.25 and Rs. 330.95 respectively. The current market cap of the company is Rs. 881.27 crore.
The promoters holding in the company stood at 68.09%, while Institutions and Non-Institutions held 1.58% and 30.33% respectively.
Jagsonpal Pharmaceutical has launched MemUp, India’s first hormone replacement therapy (HRT) featuring USFDA-approved combination of bio-identical estradiol and bio-identical progesterone in a single daily oral capsule. MemUp marks a significant advancement in women’s healthcare, offering a ground-breaking solution for the management of vasomotor symptoms of menopause like hot flashes, night sweats and sleep issues.
MemUp is designed to specifically address this gap and support the urgent need for innovative and effective treatments. The unique combination mimics the body's natural hormones, providing a more balanced and natural approach to HRT. This innovative formulation not only simplifies the treatment regimen but also enhances patient compliance and outcomes. MemUp will be made available at retailers across the country and can be purchased on the submission of a valid prescription issued by a Registered Medical Practitioner.
Jagsonpal Pharmaceutical is among India’s premiere pharmaceutical companies. The company has substantial research and development, manufacturing, marketing and distribution facilities.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1515.00 |
| Dr. Reddys Lab | 6080.25 |
| Cipla | 1565.50 |
| Zydus Lifesciences | 1110.95 |
| Lupin | 1601.00 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
